PEG-rhG-CSF in Secondary Prevention of Nab-Paclitaxel Combined With S-1 in Advanced Pancreatic Cancer
Status:
Not yet recruiting
Trial end date:
2022-02-18
Target enrollment:
Participant gender:
Summary
A prospective, open, single-arm clinical study to evaluate the efficacy and safety of
jinyouli（PEG-rhG-CSF） in the first-line treatment of advanced pancreatic cancer with
nab-paclitaxel combined with S-1.Chemotherapy regimen: (1) chemotherapy: nab-paclitaxel,
260mg/m2, intravenous infusion for 30 minutes, D1, Q3W. S-1, 80-120mg, PO BID, D1-14, Q3W.
(2) patients who met the eligibility criteria were given jinyouli injections 24 hours after
the end of intravenous infusion of nab-paclitaxel during the treatment period.